| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RVPH Stock Overview
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases.
Reviva Pharmaceuticals Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.71 |
| 52 Week High | US$4.66 |
| 52 Week Low | US$0.53 |
| Beta | 0.18 |
| 1 Month Change | -34.26% |
| 3 Month Change | -52.51% |
| 1 Year Change | -79.71% |
| 3 Year Change | -93.09% |
| 5 Year Change | n/a |
| Change since IPO | -92.69% |
Recent News & Updates
Shareholder Returns
| RVPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 10.1% | 1.1% | 3.2% |
| 1Y | -79.7% | 1.3% | -10.1% |
Return vs Industry: RVPH underperformed the US Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: RVPH underperformed the US Market which returned -11.7% over the past year.
Price Volatility
| RVPH volatility | |
|---|---|
| RVPH Average Weekly Movement | 15.2% |
| Pharmaceuticals Industry Average Movement | 11.7% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RVPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: RVPH's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 5 | Laxminarayan Bhat | https://revivapharma.com |
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company’s lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease, Parkinson’s disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity.
Reviva Pharmaceuticals Holdings Fundamentals Summary
| RVPH fundamental statistics | |
|---|---|
| Market Cap | US$10.74m |
| Earnings (TTM) | -US$14.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs RVPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.94m |
| Earnings | -US$14.94m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did RVPH perform over the long term?
See historical performance and comparisonValuation
Is RVPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RVPH?
Other financial metrics that can be useful for relative valuation.
| What is RVPH's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$10.74m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does RVPH's PB Ratio compare to its peers?
| RVPH PB Ratio vs Peers |
|---|
| Company | PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.1x | ||
CPHI China Pharma Holdings | 2.1x | n/a | US$11.3m |
BMMJ Body and Mind | 0.3x | n/a | US$10.5m |
CNSP CNS Pharmaceuticals | 0.7x | -5.0% | US$10.2m |
SNOA Sonoma Pharmaceuticals | 1.3x | n/a | US$10.2m |
RVPH Reviva Pharmaceuticals Holdings | 0.5x | -2.8% | US$10.7m |
Price-To-Book vs Peers: RVPH is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (1.1x).
Price to Earnings Ratio vs Industry
How does RVPH's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: RVPH is good value based on its Price-To-Book Ratio (0.5x) compared to the US Pharmaceuticals industry average (2x)
Price to Book Ratio vs Fair Ratio
What is RVPH's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.5x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate RVPH's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of RVPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RVPH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RVPH's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Reviva Pharmaceuticals Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-2.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RVPH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RVPH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RVPH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RVPH is forecast to have no revenue next year.
High Growth Revenue: RVPH is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RVPH's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Reviva Pharmaceuticals Holdings performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-75.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RVPH is currently unprofitable.
Growing Profit Margin: RVPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RVPH is unprofitable, and losses have increased over the past 5 years at a rate of 75.7% per year.
Accelerating Growth: Unable to compare RVPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RVPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: RVPH has a negative Return on Equity (-69.93%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Reviva Pharmaceuticals Holdings's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: RVPH's short term assets ($25.3M) exceed its short term liabilities ($3.6M).
Long Term Liabilities: RVPH's short term assets ($25.3M) exceed its long term liabilities ($283.7K).
Debt to Equity History and Analysis
Debt Level: RVPH is debt free.
Reducing Debt: RVPH had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RVPH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RVPH has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 88.3% each year.
Discover healthy companies
Dividend
What is Reviva Pharmaceuticals Holdings's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RVPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RVPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RVPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RVPH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RVPH has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.7yrs
Average board tenure
CEO
Laxminarayan Bhat (56 yo)
16.25yrs
Tenure
US$600,054
Compensation
Dr. Laxminarayan Bhat, Ph D., serves as the Founder of Reviva Pharmaceuticals Holdings, Inc. since 2006 and has been its Director since 2006 and serves as its President and Chief Executive Officer since Ma...
CEO Compensation Analysis
Compensation vs Market: Laxminarayan's total compensation ($USD600.05K) is about average for companies of similar size in the US market ($USD763.69K).
Compensation vs Earnings: Laxminarayan's compensation has increased whilst the company is unprofitable.
Board Members
Experienced Board: RVPH's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RVPH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Reviva Pharmaceuticals Holdings, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Reviva Pharmaceuticals Holdings, Inc.
- Ticker: RVPH
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$10.745m
- Shares outstanding: 15.13m
- Website: https://revivapharma.com
Number of Employees
Location
- Reviva Pharmaceuticals Holdings, Inc.
- 19925 Stevens Creek Boulevard
- Suite 100
- Cupertino
- California
- 95014
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/12 00:00 |
| End of Day Share Price | 2022/08/12 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.